Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.

Cancer · 2023 · PMC10092585 · PMID 36308296

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

At cycles 12 and 15, the LS mean changes from baseline in the cemiplimab group were numerically higher than in the chemotherapy group but failed to reach statistical significance, likely because of the large variability and small sample size in the chemotherapy group.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.